RxDoctor Payments Data

Marie Kennedy

Gerontology · Huntsville, ALNPI 1669865234

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Pfizer at 25.2% of the total. Reporting peaked in 2022 at $452 and has fallen 66.5% since, to $151 in 2025.

$875in general payments, 2019–2025

Across 22 payments — averaging $39.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$221
  • Boehringer Ingelheim$180
  • Boston Scientific$132
  • Alnylam Pharmaceuticals Inc.$129
  • Actelion Pharmaceuticals US, Inc.$105
  • E.r. Squibb & Sons, L.L.C.$47
  • plus $61 from 2 others

What the payments were for

  • Food & beverage$875100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$875 in reported general payments places this provider in the 65th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$45,549
Medicare patients
282
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan118$106,118
FarxigaDapagliflozin Propanediol35$28,506
JardianceEmpagliflozin26$17,645
Hydralazine Hcl98$1,473
Isosorbide Dinitrate13$1,427
Carvedilol115$941
Torsemide55$864
Spironolactone122$677
Metoprolol Succinate55$495
Isosorbide Mononitrate ErIsosorbide Mononitrate24$419
Valsartan27$398
Potassium Chloride17$317
Furosemide61$251
Losartan Potassium14$200
Lisinopril17$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22$106,118118 claims
Boehringer IngelheimJardiance$180$17,64526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 143 gerontology providers in Alabama.

Other gerontology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →